Latest Content

The FDA has approved ensitrelvir (Xocova) for postexposure prophylaxis of COVID-19 in adults and children 12 years or older, making it the first and only oral antiviral authorized to help prevent symptomatic infection after exposure.

Modeling of the ACIP recommendation to replace universal birth-dose HepB vaccination with vaccination based on "shared decision" and maternal status shows substantially more maternal screening or vaccinating infants of unscreened mothers will be necessary to mitigate increase in infections.

Traws is studying an oral combination antiviral for hantavirus and Ebola, but no animal or human efficacy data have been reported.

Fluoroquinolones are broadly active and convenient, but black box warnings and resistance concerns have reshaped when and how clinicians should use them.

A 12-month longitudinal analysis of 852 children found two-thirds of those with confirmed SARS-CoV-2 infection reported at least one of 20 post-COVID symptoms, with anxiety and depression equally prevalent in uninfected peers.

A 5-day course of nitrofurantoin was found superior to single-dose fosfomycin for uncomplicated UTI in women, prompting investigators to recommend choosing efficacy over convenience.

In the second episode with Emory’s Gavin Harris, MD, he offers some insights about treating patients with the Andes virus, including supportive care as well as investigational antivirals.

Incoming SIDP President Lisa Dumkow, PharmD, FIDP, BCIDP, highlighted plans to expand mentorship, strengthen research collaboration, and move the organization's initiatives forward. She also offered insights into the new combined MAD-ID/SIDP meeting.

At the 2026 MAD-ID/SIDP meeting, Zachary Nelson, PharmD, MPH, BCIDP, discussed how urine-specific breakpoints can improve treatment decisions for urinary tract infections by accounting for drug concentrations in the urinary tract rather than relying solely on traditional blood-level interpretations.

C difficile deaths drop after 2011, but seniors, Black Americans, and rural areas still see higher mortality.

Emory’s Gavin Harris, MD, discusses how getting patients this type of treatment is essential to reducing the severity of disease, as well as adapting the four “I’s” algorithm in dealing with high-consequence infectious disease outbreaks.

The FDA has approved bulevirtide-gmod (Hepcludex), the first approved US therapy for HPDV with no prior treatment options.

In the second episode of our conversation with David Wohl, MD, with the Institute for Global Health and Infectious Diseases at the UNC School of Medicine, he discusses the person-to person transmission, if we expect to see more cases and how it presents, including a serious complication of the virus.